| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 01/25/1992 | WO1992001709A1 Process for synthesizing peptides |
| 01/25/1992 | WO1992001469A1 A composition providing improved clearance of bioactive substances from the bloodstream |
| 01/25/1992 | CA2087971A1 Composition providing improved clearance of bioactive substances from the bloodstream |
| 01/25/1992 | CA2086928A1 Polypeptide compounds having growth hormone releasing activity |
| 01/25/1992 | CA2086416A1 Process for synthesizing peptides |
| 01/25/1992 | CA2066749A1 Analogs of hirudin |
| 01/25/1992 | CA2047527A1 Method for administering a therapeutic anticoagulant |
| 01/24/1992 | CA2047618A1 Use of particular compounds for manufacture of pharmaceutical formulations for metabolic treatments |
| 01/24/1992 | CA2047540A1 Continuous release pharmaceutical compositions |
| 01/24/1992 | CA2047306A1 Mutant bacterium clostridium histolyticum, a process for the obtaining thereof, and its use in the production of clostripain-free collagenase |
| 01/23/1992 | WO1992001059A1 Cdr grafted anti-cea antibodies and their production |
| 01/23/1992 | WO1992001054A1 Substance with interleukin-8 inhibiting activity and process for its preparation |
| 01/23/1992 | WO1992001052A1 Dna coding for human fk506-binding protein and expression thereof |
| 01/23/1992 | WO1992001050A1 Novel receptor-type phosphotyrosine phosphatase |
| 01/23/1992 | WO1992001049A2 Cd53 cell surface antigen and use thereof |
| 01/23/1992 | WO1992001048A1 Production of aprotinin in methylotrophic yeast cells |
| 01/23/1992 | WO1992001044A1 Mouse/human heterohybrid cell line el41 and methods for the production of human monoclonal antibodies |
| 01/23/1992 | WO1992001000A1 Basophil granule proteins |
| 01/23/1992 | WO1992000999A1 Fibroblast growth factor receptors |
| 01/23/1992 | WO1992000994A1 Growth-promoting agent |
| 01/23/1992 | WO1992000986A1 Nucleic acid sequences encoding a human dopamine d1 receptor |
| 01/23/1992 | WO1992000956A1 Inhibitors of aspartic proteases |
| 01/23/1992 | WO1992000954A1 Aspartic protease inhibitors |
| 01/23/1992 | WO1992000948A1 Inhibitors of retroviral proteases |
| 01/23/1992 | WO1992000757A1 Diagnosis of metastatic cancer by the mts-1 gene |
| 01/23/1992 | WO1992000756A1 Immune suppressive product |
| 01/23/1992 | WO1992000751A1 A pharmaceutical composition comprising a cell adhesion molecule |
| 01/23/1992 | WO1992000743A1 Use of taurolidine and/or taurultam for the treatment of tumours |
| 01/23/1992 | WO1991019793A3 Hybrid plasminogen activators |
| 01/23/1992 | CA2087019A1 Nucleic acid sequences encoding a human dopamine d1 receptor |
| 01/23/1992 | CA2087008A1 Novel receptor-type phosphotyrosine phosphatase |
| 01/23/1992 | CA2086932A1 Basophil granule proteins |
| 01/23/1992 | CA2086829A1 Diagnosis of metastatic cancer by the mts-1 gene |
| 01/22/1992 | EP0467839A1 In vitro processing of fusion proteins |
| 01/22/1992 | EP0467701A2 Cyclic HIV principal neutralizing determinant peptides |
| 01/22/1992 | EP0467700A2 Coconjugate vaccines comprising immunogenic protein, HIV related peptides, and anionic moieties |
| 01/22/1992 | EP0467699A2 Cyclic HIV principal neutralizing determinant peptides |
| 01/22/1992 | EP0467536A2 Method of treating bladder cancer cells |
| 01/22/1992 | EP0467433A1 Use of a centrally acting ATCH analog in the manufacture of a medicament |
| 01/22/1992 | EP0467416A1 Antibody compositions of therapeutic agents having an extended serum half-life |
| 01/22/1992 | EP0467389A2 Drug delivery system involving interaction between protein or polypeptide and hydrophobic biodegradable polymer |
| 01/22/1992 | EP0467366A2 Cell membrane glycoprotein correlated with resistance to platinum-containing antineoplastic agents |
| 01/22/1992 | EP0467349A1 Regulation of gene expression by employing translational inhibition utilizing mRNA interfering complementary RNA |
| 01/22/1992 | EP0467279A2 Polypeptides having c-AMP producing activity |
| 01/22/1992 | EP0466966A1 Synthetic chondroitin sulfate proteoglycan and process for producing the same |
| 01/22/1992 | EP0466944A1 4h-3,1-benzoxazin-4-one compound and elastase inhibitor composition containing the same |
| 01/22/1992 | EP0466912A1 Glutathione-s-transferase sm26 of s. mansoni |
| 01/22/1992 | EP0466854A1 T cell growth factor |
| 01/22/1992 | EP0466817A1 Recombinant trichosanthin and coding sequence |
| 01/22/1992 | EP0466815A1 Infectious targetted replication-defective virion |
| 01/22/1992 | EP0466806A1 Phosphatidylinositol linking of proteins |
| 01/22/1992 | EP0466780A1 Megakaryocyte growth promoting activity |
| 01/22/1992 | EP0466769A1 Reducing post-prandial plasma large neutral amino acid concentrations. |
| 01/22/1992 | CN1058022A Method for preparing interferon alpha-2 crystals |
| 01/21/1992 | WO1992001474A1 Heterobifunctional reagents and conjugates with oxaalkylene units for amphiphilic bridge structures |
| 01/21/1992 | US5082927 Genetic engineering, immunology |
| 01/21/1992 | US5082926 Polypeptide with type iv collagen cell adhesion, spreading and motility activity |
| 01/21/1992 | US5082774 Genetic engineering |
| 01/21/1992 | US5082670 Method of grafting genetically modified cells to treat defects, disease or damage or the central nervous system |
| 01/21/1992 | US5082658 Antitumor |
| 01/21/1992 | US5082657 Leukoregulin, an antitumor lymphokine, and its therapeutic uses |
| 01/21/1992 | CA2087163A1 Heterobifunctional reagents and conjugates with oxaalkylene units for amphiphilic bridge structures |
| 01/21/1992 | CA2047482A1 Solid pharmaceutical composition |
| 01/21/1992 | CA1294738C Chemical derivatives of ghl-cu |
| 01/21/1992 | CA1294737C Cck antagonists |
| 01/21/1992 | CA1294736C Renin inhibitors containing 5-amino-2,5-disubstituted- 4-hydroxypentanoic acid residues |
| 01/21/1992 | CA1294546C Wound healing composition containing collagen |
| 01/20/1992 | WO1992001472A1 Multivalent anti-cytokine immunoglobulins |
| 01/20/1992 | WO1992001464A1 Inhibition of mac-1 receptor binding to fibrinogen using d30 homologs |
| 01/20/1992 | CA2087541A1 Multivalent anti-cytokine immunoglobulins |
| 01/20/1992 | CA2087169A1 Inhibition of mac-1 receptor binding to fibrinogen using d30 homologs |
| 01/20/1992 | CA2047317A1 Amphiphilic peptide compositions and analogues thereof |
| 01/20/1992 | CA2047078A1 Cyclic hiv principal neutralizing determinant peptides |
| 01/20/1992 | CA2047073A1 Coconjugate vaccines comprising immunogenic protein, hiv related peptides, and anionic moieties |
| 01/20/1992 | CA2047043A1 Class ii protein of the outer membrane of neisseria meningitidis having immune enhancement properties |
| 01/20/1992 | CA2047042A1 Cyclic hiv principal neutralizing determinant peptides |
| 01/20/1992 | CA2047033A1 Cyclic hiv principal neutralizing determinant peptides |
| 01/20/1992 | CA2047030A1 Class ii protein of the outer membrane of neisseria meningitidis having immunologic carrier and enhancement properties |
| 01/20/1992 | CA2045231A1 Cell membrane glycoprotein correlated with resistance to platinum-containing antineoplastic agents |
| 01/19/1992 | WO1992001475A1 Compositions based on active principles of hydrophobic medicaments solubilizable in an aqueous solvent |
| 01/19/1992 | WO1992001467A1 Method for treating viral infections using oxidized lipoproteins |
| 01/19/1992 | CA2087536A1 Compositions based on active ingredients of hydrophobic drugs that can be sulubilized in an aqueous solvent |
| 01/19/1992 | CA2086921A1 Method for treating viral infections using oxidized lipoproteins |
| 01/19/1992 | CA2047313A1 Polypeptides |
| 01/19/1992 | CA2046754A1 Dna coding for a human vasoconstrictive peptide and use thereof |
| 01/19/1992 | CA2045714A1 Use of a centrally acting acth analog in the manufacture of a medicament |
| 01/18/1992 | CA2035836A1 Reduction of oxyradical damage in biomedical applications |
| 01/17/1992 | CA2047091A1 Method for producing gene protein products |
| 01/17/1992 | CA2045842A1 Dna capable of site-specific integration into mycobacteria |
| 01/16/1992 | DE4022267A1 New N-acyl-peptide(s) with good solubility and stability |
| 01/16/1992 | DE4021917A1 O-glycosylated alpha-interferon, used as medicament - isolated following secretion into conditioned medium of mammalian cells contg. a suitable expression plasmid |
| 01/15/1992 | EP0466505A2 Artificial antibody |
| 01/15/1992 | EP0466498A1 Physiologically active peptides having immunoregulatory activities |
| 01/15/1992 | EP0466440A2 Anti-metastatic factor |
| 01/15/1992 | EP0466315A2 Compositions containing xylan sulphates for affecting growth factor function and for inhibiting fibroblast proliferation |
| 01/15/1992 | EP0466222A1 Ribosome-inactivating proteins, inactive precursor forms thereof, a process for making and a method of using |
| 01/15/1992 | EP0466199A1 Polypeptide fragments of factor VIIIc, corresponding probes and DNA sequences and DNA constructs |
| 01/15/1992 | EP0466175A1 Porcine CNP gene and precursor protein |
| 01/15/1992 | EP0466174A1 Novel physiologically active porcine peptide (CNP-53) |
| 01/15/1992 | EP0466030A2 N-acyl dipeptides and their use |